201 related articles for article (PubMed ID: 37740183)
1. The application of HER2 and CD47 CAR-macrophage in ovarian cancer.
Chen Y; Zhu X; Liu H; Wang C; Chen Y; Wang H; Fang Y; Wu X; Xu Y; Li C; Lv X; Huang J; Han X; Li R; Hong W; Yu Z; Wei W; Tu J
J Transl Med; 2023 Sep; 21(1):654. PubMed ID: 37740183
[TBL] [Abstract][Full Text] [Related]
2. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors.
Huo Y; Zhang H; Sa L; Zheng W; He Y; Lyu H; Sun M; Zhang L; Shan L; Yang A; Wang T
J Transl Med; 2023 Mar; 21(1):225. PubMed ID: 36978075
[TBL] [Abstract][Full Text] [Related]
3. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
[TBL] [Abstract][Full Text] [Related]
4. Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment.
Qiu Y; Liao P; Wang H; Chen J; Hu Y; Hu R; Zhang H; Li Z; Cao M; Yang Y; Li M; Xie X; Li Y
Int J Biol Sci; 2023; 19(15):4948-4966. PubMed ID: 37781520
[TBL] [Abstract][Full Text] [Related]
5. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
6. A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety.
Li Y; Liu J; Chen W; Wang W; Yang F; Liu X; Sheng Y; Du K; He M; Lyu X; Li H; Zhao L; Wei Z; Wang F; Zheng S; Sui J
J Hematol Oncol; 2023 Jan; 16(1):2. PubMed ID: 36650558
[TBL] [Abstract][Full Text] [Related]
7. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
[TBL] [Abstract][Full Text] [Related]
8. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
9. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
11. CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth.
Golubovskaya V; Berahovich R; Zhou H; Xu S; Harto H; Li L; Chao CC; Mao MM; Wu L
Cancers (Basel); 2017 Oct; 9(10):. PubMed ID: 29065481
[TBL] [Abstract][Full Text] [Related]
12. Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer.
Shimizu A; Sawada K; Kobayashi M; Yamamoto M; Yagi T; Kinose Y; Kodama M; Hashimoto K; Kimura T
Mol Cancer Res; 2021 Sep; 19(9):1583-1595. PubMed ID: 34016744
[TBL] [Abstract][Full Text] [Related]
13. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.
Sakakura K; Takahashi H; Kaira K; Toyoda M; Murata T; Ohnishi H; Oyama T; Chikamatsu K
Lab Invest; 2016 Sep; 96(9):994-1003. PubMed ID: 27322955
[TBL] [Abstract][Full Text] [Related]
14. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
15. Restoration of miR-340 controls pancreatic cancer cell
Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
[TBL] [Abstract][Full Text] [Related]
16. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
[TBL] [Abstract][Full Text] [Related]
17. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
18. CD47 expression is critical for CAR T-cell survival in vivo.
Beckett AN; Chockley P; Pruett-Miller SM; Nguyen P; Vogel P; Sheppard H; Krenciute G; Gottschalk S; DeRenzo C
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918226
[TBL] [Abstract][Full Text] [Related]
19. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
[TBL] [Abstract][Full Text] [Related]
20. Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review.
Lecoultre M; Dutoit V; Walker PR
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
